Stephen Basso

Director of Finance/CFO bei INNOVIVA, INC.

Vermögen: 181 319 $ am 30.04.2024

58 Jahre

Health Technology

Consumer Services

Aktive Positionen von Stephen Basso

Unternehmen	Position	Beginn	Ende
INNOVIVA, INC.	Director of Finance/CFO	21.08.2023	-

Unternehmen	Position	Beginn	Ende
INOZYME PHARMA, INC.	Comptroller/Controller/Auditor	01.10.2017	14.05.2021
INOZYME PHARMA, INC.	Director of Finance/CFO	01.10.2017	14.05.2021
ALEXION PHARMACEUTICALS, INC.	Corporate Officer/Principal	01.01.2009	01.05.2017
Cybrexa, Inc. Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT.	Chief Operating Officer	-	-
	Director of Finance/CFO	-	-

Boston College	Masters Business Admin
Providence College	Undergraduate Degree

International

Vereinigte Staaten

Operativ

Director of Finance/CFO	3
Comptroller/Controller/Auditor	1
Corporate Officer/Principal	1

Sektoral

Health Technology	5
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
INNOVIVA, INC.	Health Technology
INOZYME PHARMA, INC.	Health Technology

Private Unternehmen	2
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.	Health Technology
Cybrexa, Inc. Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT.	Health Technology

Private Unternehmen

Health Technology